Sugi Predict

Sugi Predict / Compounds / SCHEMBL17440686

SCHEMBL17440686

SCHEMBL17440686

COc1cc(F)c(C=O)c(Br)c1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ERN1 O75460 5/20 0.44
▸ PRKDC P78527 1/20 0.44
▸ TAAR1 Q96RJ0 1/20 0.40
▸ CYP1A1 P04798 2/20 0.38
▸ CYP1B1 Q16678 2/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.37
▸ CYP2A6 P11509 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ TRIM24 O15164 1/20 0.34
▸ TYR P14679 1/20 0.34
▸ TRIM33 Q9UPN9 1/20 0.34
▸ NQO2 P16083 1/20 0.34
▸ HDAC1 Q13547 1/20 0.34
▸ CA12 O43570 1/20 0.34
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ CA9 Q16790 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL954134 0.88 ERN1 (0.50) ERN1PRKDCTAAR1CYP1A1CYP1B1
SCHEMBL28624326 0.82 LMNA (0.47) ERN1PRKDCALDH1A1LMNACA12
SCHEMBL31550130 0.82 ALDH1A3 (0.41) ERN1PRKDCCYP1A2ALDH1A1LMNA
SCHEMBL1645590 0.81 ERN1 (0.62) ERN1PRKDCTAAR1CYP1A1CYP1B1
SCHEMBL17440697 0.81 NPC1 (0.52) ALDH1A1LMNA
SCHEMBL1459113 0.79 ERN1 (0.43) ERN1TAAR1CYP1A1CYP1B1CYP1A2
SCHEMBL15348517 0.79 ERN1 (0.66) ERN1TAAR1CYP1A1CYP1B1ALDH1A1
SCHEMBL13982472 0.79 ERN1 (0.44) ERN1TAAR1CYP1A1CYP1B1CYP1A2
SCHEMBL30230047 0.78 ERN1 (0.65) ERN1PRKDCCYP1A1CYP1B1CYP1A2
SCHEMBL349075 0.78 ERN1 (0.65) ERN1PRKDCCYP1A1CYP1B1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042759-A1 INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) 2026-02-12 — — US disclosed
US-20250388577-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LTD (GB) 2025-12-25 — — US disclosed
US-12466823-B2 Inhibitor containing bicyclic derivative, preparation method therefor and use thereof SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2025-11-11 — — US disclosed
US-12358915-B2 METTL3 inhibitory compounds STORM Therapeutics Ltd. (GB) 2025-07-15 — — US disclosed
EP-3971187-B1 INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) 2025-05-07 — — EP disclosed
WO-2023214325-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AND USES THEREOF AS TET2 INHIBITORS NOVARTIS AG (CH) 2023-11-09 — — WO disclosed
US-11731953-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-08-22 — — US disclosed
US-11731953-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-08-22 — — US disclosed
US-11731953-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-08-22 — — US disclosed
CN-111971277-B Benzothiophenes and related compounds as STING agonists 默沙东有限责任公司 2023-06-06 — — CN disclosed
US-20190300513-A1 STING AGONIST COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2019-10-03 — — US disclosed
US-20190248787-A1 IRAK4 INHIBITING AGENTS BIOGEN MA INC. 2019-08-15 — — US disclosed
US-20190248787-A1 IRAK4 INHIBITING AGENTS BIOGEN MA INC. 2019-08-15 — — US disclosed
US-10246456-B2 IRAK4 inhibiting agents BIOGEN MA INC. (US) 2019-04-02 — — US disclosed
US-10246456-B2 IRAK4 inhibiting agents BIOGEN MA INC. (US) 2019-04-02 — — US disclosed
US-20170204093-A1 IRAK4 INHIBITING AGENTS BIOGEN MA INC. 2017-07-20 — — US disclosed
US-20170204093-A1 IRAK4 INHIBITING AGENTS BIOGEN MA INC. 2017-07-20 — — US disclosed
US-20170204093-A1 IRAK4 INHIBITING AGENTS BIOGEN MA INC. 2017-07-20 — — US disclosed
WO-2016011390-A1 IRAK4 INHIBITING AGENTS BIOGEN MA INC. (US) 2016-01-21 — — WO disclosed
WO-2016011390-A1 IRAK4 INHIBITING AGENTS BIOGEN MA INC. (US) 2016-01-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12358915-B2 METTL3 inhibitory compounds METTL3, METTL16, DIMT1 ERN1 1804/4885PRKDC 627/4885TAAR1 4143/4885
US-20190300513-A1 STING AGONIST COMPOUNDS STING1, CGAS, IRF3 ERN1 486/4885PRKDC 2048/4885TAAR1 1574/4885
US-10246456-B2 IRAK4 inhibiting agents IRAK4, IRAK1, IRAK2 ERN1 197/4885PRKDC 986/4885TAAR1 3270/4885
US-20260042759-A1 INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF FAR1, CYP4A11, CYP11B1 ERN1 2866/4885PRKDC 4776/4885TAAR1 381/4885
US-11731953-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS ERN1 2304/4885PRKDC 218/4885TAAR1 4782/4885
US-20250388577-A1 METTL3 INHIBITORY COMPOUNDS METTL3, RNMT, TPMT ERN1 1035/4885PRKDC 971/4885TAAR1 1444/4885
US-12466823-B2 Inhibitor containing bicyclic derivative, preparation method therefor and use thereof RET, REL, GOT1 ERN1 2746/4885PRKDC 3672/4885TAAR1 3862/4885
US-20170204093-A1 IRAK4 INHIBITING AGENTS IRAK4, IRAK1, IRAK2 ERN1 197/4885PRKDC 986/4885TAAR1 3270/4885
US-20190248787-A1 IRAK4 INHIBITING AGENTS IRAK4, IRAK1, IRAK2 ERN1 170/4885PRKDC 657/4885TAAR1 3397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.